|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00517543 |
This study is being conducted to measure the amount of study drug that is in your blood after you receive a different type of tablet in each of four study visits.
Condition | Intervention | Phase |
COPD Rheumatoid Arthritis Atherosclerosis |
Drug: GW856553 |
Phase I |
MedlinePlus related topics: | Rheumatoid Arthritis |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Dose Comparison, Crossover Assignment, Bio-equivalence Study |
Official Title: | A Randomized, Open Label, 4 Period Crossover Study in Healthy Subjects to Determine the Effect of Particle Size on the Pharmacokinetics of a Single mg Dose of GW856553 |
Enrollment: | 36 |
Study Start Date: | August 2007 |
Study Completion Date: | October 2007 |
Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
To be eligible, female subjects must have a negative pregnancy test (i.e. serum hCG test) and be of:
Exclusion Criteria:
Study ID Numbers: | 109385 |
First Received: | August 16, 2007 |
Last Updated: | April 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00517543 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|